Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012

Cortés, Isabel; Pérez-Camarero, S.; Llano, Juan del; Peña, Luz María Adriana Balderas; Hidalgo, Álvaro

doi:10.1016/j.vaccine.2013.05.097

Cited by 19 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the important economic aspects, all the highly significant studies available in the literature confirm that pneumococcal vaccinations are cost-effective in children, adults, and in elderly patients [ 91 , 92 ]. The great clinical impact of pneumococcal immunization is now evident in adults and in the elderly, and pharmaco-economic studies and literature reviews support and confirm the cost-effective profile of pneumococcal vaccination in all ages [ 93 , 94 ]. Although the PPV23 vaccination is usually convenient, further scientific evidence should be considered in the decision-making process prior to implementation, and this due to the limited duration of immunological protection of this vaccine.…”

Section: Medical Costsmentioning

confidence: 99%

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance

et al. 2021

View full text Add to dashboard Cite

Streptococcus pneumoniae related diseases are a leading cause of morbidity and mortality, especially in children and in the elderly population. It is transmitted to other individuals through droplets and it can spread to other parts of the human host, causing a wide spectrum of clinical syndromes, affecting between 10 and 100 cases per 100,000 people in Europe and the USA. In order to reduce morbidity and mortality caused by this agent, pneumococcal vaccines have been developed over the years and have shown incredible effectiveness in reducing the spread of this bacterium and the development of related diseases, obtaining a significant reduction in mortality, especially in developing countries. However, considerable problems are emerging mainly due to the replacement phenomenon, multi-drug resistance, and the high production costs of conjugated vaccines. There is still a debate about the indications given by various countries to different age groups; this is one of the reasons for the diffusion of different serotypes. To cope with these problems, significant efforts have been made in the research field to further improve vaccination serotypes coverage. On the other hand, an equally important commitment by health care systems to all age group populations is needed to improve vaccination coverage.

show abstract

Section: Medical Costsmentioning

confidence: 99%

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance

et al. 2021

View full text Add to dashboard Cite

show abstract

“…En este ámbito, los de tipo coste-utilidad están adquiriendo cada día mayor relevancia al incorporar la dimensión de la calidad de vida, unida al hard endpoint más importante, la muerte. Así, en la actualidad se publican con frecuencia revisiones sistemáticas de las evaluaciones económicas efectuadas en una gran variedad de tratamientos, como cáncer de pulmón de células no pequeñas (35) , esquizofrenia (36) , Alzheimer (37) , tuberculosis resistente (38) , púrpura trombocitopénica (39) , o incluso, análisis de las evaluaciones económicas efectuadas en nuestro país, durante los últimos años, en campos más amplios como el cáncer (40) , las vacunas (41) o los trastornos mentales (42) .…”

Section: Eficiencia De Los Tratamientos Farmacológicosunclassified

Cuadernos de Evaluación Sanitaria. Nº 6. Modelos de evaluación económica y su aplicación en España

Hidalgo¹,

Llano²

2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Meanwhile, many countries have yet to review and synthesize their own research in this area. One of the few examples is Spain, who recently released two comprehensive systematic reviews on Spanish economic evaluations of vaccinations completed between 1990 and 2012 [9, 10]. …”

Section: Introductionmentioning

confidence: 99%

Economic evaluations of vaccines in Canada: a scoping review

Rafferty

Gagnon

Farag

et al. 2017

Cost Eff Resour Alloc

View full text Add to dashboard Cite

BackgroundThis study aims to summarise and describe the evolution of published economic evaluations of vaccines in Canada, thereby outlining the current state of this expanding and meaningful research.MethodsUsing Arksey and O’Malley’s scoping review framework we assembled relevant research from both academic and grey literature. Following abstract and full-text review we identified 60 articles to be included in the final analysis.ResultsWe found that since 1988 there has been a steady increase in the number of economic evaluations on vaccines in Canada. Many of these studies focus on the more recently licensed vaccines, such as influenza (16.7%), human papillomavirus (15.0%) and pneumococcal disease (15.0%). Since 2010 economic evaluations of vaccines have shown increased adherence to economic evaluation guidelines (OR = 4.6, CI 1.33, 18.7), suggesting there has been improvement in the consistency and transparency of these studies. However, there remains room for improvement, for instance, we found evidence that studies who stated a conflict of interest are more likely to assert the vaccine of interest was cost-effective (OR = 7.4; CI 1.04, 17.8). Furthermore, most reports use static models that do not consider herd immunity, and only a few evaluate vaccines post-implementation (ex-post) and traveller’s vaccinations.ConclusionResearchers should examine identified research gaps and continue to improve standardization and transparency when reporting to ensure economic evaluations of vaccines best meet the needs of policy-makers, other researchers and the public.Electronic supplementary materialThe online version of this article (doi:10.1186/s12962-017-0069-4) contains supplementary material, which is available to authorized users.

show abstract

Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012

Cited by 19 publications

References 22 publications

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance

Cuadernos de Evaluación Sanitaria. Nº 6. Modelos de evaluación económica y su aplicación en España

Economic evaluations of vaccines in Canada: a scoping review

Contact Info

Product

Resources

About